Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Regeneron Pharmaceuticals (NQ: REGN )

993.10 +5.83 (+0.59%)
Streaming Delayed Price Updated: 10:08 AM EDT, May 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Regeneron Pharmaceuticals

< Previous 1 2
...
30 31 32 33 34 35 36 37 Next >
Market Briefing For Monday, Aug. 2
We're 'not' in a global financial crisis; but we are failing the 'synchronized global recovery', due to the worldwide pandemic. 
Via Talk Markets
The Daily Biotech Pulse: Merck's Disappointing Q2, Atreca Falls On Data, FDA Nod For Viatris, Nuvalent, Icosavax IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 28) AbbVie Inc. (NYSE: ABBV)... 
Via Benzinga
Exposures Product Safety
Regeneron - Sanofi's Dupixent Improves Itch, Hives In Inflammatory Skin Disease Patients
Sanofi SA (NASDAQ: SNY) and Regeneron Pharmaceuticals Inc's (NASDAQ: REGN) have announced topline results from Phase 3 trial evaluating Dupixent (... 
Via Benzinga
Is This Mid-Cap Biotech Stock a Buy Now?
This mid-cap growth stock could be a long-term winner. 
Via The Motley Fool
Topics Initial Public Offering
Exposures Securities Market
Market Briefing For Thursday, July 29
Disarming SARS-CoV-2 with pharmaceutical drugs is the 'holy grail' to end the COVID-19 panic, and generally eliminate the panic pressures for vaccines. 
Via Talk Markets
Exposures COVID-19
3 Things About Regeneron That Smart Investors Know
The biotech's COVID-19 antibody cocktail made headlines last year, but there's a bigger story here. 
Via The Motley Fool
Topics Government
Exposures COVID-19 Political
3 Reasons Caribou Biosciences Could Be the Best Gene-Editing Stock for Your Portfolio
The company has a pedigree and a novel approach that could put it at the top of the CRISPR heap. 
Via The Motley Fool
The Daily Biotech Pulse: ObsEva Surges On Out-Licensing Deal, EyeGate Appoints New CEO, 2 Positive Catalysts For Merck, Candel Therapeutics Debuts
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 26) Absci, CORP (NASDAQ: ABSI... 
Via Benzinga
Maravai Lifesciences Stock Clears Technical Benchmark, Hitting 80-Plus RS Rating
Maravai Lifesciences sees its Relative Strength Rating enter the 80-plus level. 
Via Investor's Business Daily
Sanofi-Regeneron's COPD Drug Fails In Mid-Stage Trial, But Shows Potential Benefit In Subgroup of Former Smokers
Sanofi SA (NASDAQ: SNY) and Regeneron Pharmaceuticals Inc (NASDAQ: REGN) started their collaboration in chronic obstructive pulmonary disorder (COPD) to target all... 
Via Benzinga
Alnylam Pharmaceuticals Stock Sees Healthy Rising Relative Strength Rating
The Relative Strength (RS) Rating for Alnylam Pharmaceuticals stock climbed into a new percentile Monday, as it got a lift from 63 to 71. 
Via Investor's Business Daily
C4 Therapeutics Stock Enters Leadership Territory
A Relative Strength Rating upgrade for C4 Therapeutics shows improving technical performance. 
Via Investor's Business Daily
AMD And Biogen Lead The QQQ Lower Thursday
U.S. indices were trading lower Thursday as investors weigh Fed Chair Powell’s comments on inflation to the Senate banking panel. ... 
Via Benzinga
Topics Economy
Exposures Interest Rates
5 French Stocks To Consider For Bastille Day
Bastille Day is France’s National Day, celebrating the Storming of the Bastille on July 14, 1789, a key turning point in the French Revolution. And while the French concept... 
Via Benzinga
Is This Coronavirus Stock Undervalued?
This biotech giant might be down, but it isn't out just yet. 
Via The Motley Fool
Exposures COVID-19
2 Biotech Stocks That are Dirt Cheap Right Now
Biotech companies responded to the COVID-19 pandemic in a remarkable way, with vaccinations, treatments, diagnostics, and variant monitoring. 
Via Talk Markets
Exposures COVID-19
3 Top Biotech Stocks to Buy in July
Now's the time to get into these companies while their valuation is still favorable. 
Via The Motley Fool
Is It Too Late to Buy Intellia Therapeutics?
After skyrocketing 68% last week, will this stock keep running higher? 
Via The Motley Fool
Here's Why Regeneron Gained 11% Last Month
The biopharma outfit dropped news that may mean more for the medicine industry than anybody fully understands. 
Via The Motley Fool
Will an Increase in Vaccinations Hurt Regeneron's COVID Treatment Sales?
The antibody cocktail treats people with mild-to-moderate illness. 
Via The Motley Fool
Topics Cannabis
Exposures COVID-19 Cannabis
This News May Mean Billions for Regeneron
Regeneron's COVID-19 treatment is getting easier to administer -- and produce. 
Via The Motley Fool
Topics Cannabis
Exposures COVID-19 Cannabis
3 Tips for Coronavirus Investing Right Now
Whether you're a cautious or aggressive investor, there's something for you in this space. 
Via The Motley Fool
Topics Cannabis
Exposures COVID-19 Cannabis
Regeneron Discovers GPR75 Gene Mutations Can Protect Against Obesity, Begins Search For New Drugs
A team at Regeneron Pharmaceuticals Inc's (NASDAQ: REGN) Genetics Center has discovered mutations in the gene GPR75 that protect against obesity. Now, drug... 
Via Benzinga
Facebook And Nvidia Lead The QQQ Thursday
U.S. indices are trading higher following better-than-expected jobless claims, which lifted recovery sentiment to start off July. ... 
Via Benzinga
In Future CRISPR Gene Editing To Treat Diseases, Says Intellia Co-Founder: CNBC
Gene-editing technology CRISPR reached a significant milestone this week, completing its first systemic delivery as a medicine to the human body. What Happened: On Monday,... 
Via Benzinga
Can Intellia Therapeutics Turn Exciting Trial Results into Profits?
New proof-of-concept results are a big deal for the medical community, but what about for your portfolio? 
Via The Motley Fool
Exposures COVID-19
EC Selects Antibody Therapies, Arthritis Drug As Preferred COVID-19 Meds: Reuters
The European Commission (EC) picked four antibody treatments and a repurposed Eli Lilly And Co's (NYSE: LLY) rheumatoid arthritis drug for an initial... 
Via Benzinga
Exposures COVID-19
Why Regeneron Pharmaceuticals Analyst Says Competitive Concerns Are Overblown, Pipeline Opportunity Underappreciated
Regeneron Pharmaceuticals Inc.'s (NASDAQ:REGN) robust ... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 29, 2021
Upgrades For Nutrien Ltd (NYSE: 
Via Benzinga
Is Now The Time To Buy Stock In Tesla, GM Or Regeneron?
One of the most common questions traders have about stocks is “Why Is It Moving?” That’s why Benzinga created the Why I... 
Via Benzinga
< Previous 1 2
...
30 31 32 33 34 35 36 37 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.